3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, T-Cell, Peripheral
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Interventions
Rituximab
47
Cyclophosphamide
26
fludarabine
13
ibrutinib
12
Doxorubicin
11
Vincristine
10
Etoposide
10
Cytarabine
10
Prednisone
9
Bortezomib
9
pembrolizumab
7
fludarabine phosphate
6
Lenalidomide
6
Inotuzumab Ozogamicin
6
obinutuzumab
5
Mycophenolic Acid
5
Melphalan
5
Carmustine
5
tositumomab I-131
4
ibritumomab tiuxetan
4
Tacrolimus
4
Prednisolone
4
Methotrexate
4
Gemcitabine
4
Bendamustine Hydrochloride
4
Antilymphocyte Serum
4
tocilizumab
3
tazemetostat
3
Whole-Body Irradiation
3
Vorinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, B-Cell
×
tenalisib
×
Clear all
NCT02017613
2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1
Completed
35 enrolled